PCMI
NKTR icon

Princeton Capital Management Inc’s Nektar Therapeutics NKTR Stock Holding History

Princeton Capital Management Inc’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,697
Closed -$640K – 72
2013
Q2 		$640K Buy
+3,697
New +$567K 0.61% 46

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Princeton Capital Management Inc's NKTR Position: Q3 2013 in Review

Princeton Capital Management Inc sold out of Nektar Therapeutics (NKTR) in Q3 2013, closing a stake of 3,697 shares — an estimated $640K sold.

Princeton Capital Management Inc first reported a position in NKTR in Q2 2013 and held it in 1 quarter. The position peaked at $640K in Q2 2013. 142 funds tracked by Wall St. Rank hold NKTR as of Q3 2013.

  • Princeton Capital Management Inc reported no remaining Nektar Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Princeton Capital Management Inc sold 3,697 Nektar Therapeutics shares in Q3 2013, an estimated $640K.
  • Princeton Capital Management Inc first reported a position in Nektar Therapeutics in Q2 2013 and held it in 1 quarter.
  • Princeton Capital Management Inc's Nektar Therapeutics position peaked at $640K in Q2 2013.
  • 142 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2013.

Based on Princeton Capital Management Inc's 13F filing for Q3 2013, filed 8 Nov 2013.